How long can Olaparib last without recurrence?

Data from the SOLO-1 trial, which evaluated the efficacy of olaparib (300 mg twice daily) as maintenance monotherapy (compared with placebo) in patients with newly diagnosed advanced ovarian cancer following the longest follow-up of any PARP inhibitor, found that the benefits of maintenance olaparib persisted after the end of treatment. Long-term results from this trial suggest that maintenance olaparib more than doubles 5-year disease-free survival in patients with newly diagnosedBRCA-mutated advanced ovarian cancer. More than half of the women in baseline complete remission received maintenance treatment with olaparib for 2 years and remained relapse-free after 5 years.